参考资料：
Shu S, et al. Response and resistance to BET bromodomain inhibitors intriple negative breast cancer. Nature. 2016; 529: 413–417.
Shu S, Wu HJ, et al. Synthetic Lethal and Resistance Interactions withBET Bromodomain Inhibitors in Triple-Negative Breast Cancer. Mol Cell.2020, doi: 10.1016/j.molcel.2020.
Ge JY, Shu S, et al. Acquired resistance to combined BET and CDK4/6inhibition in triple-negative breast cancer. Nat Commun. 2020, doi: 10.1038/s41467-020-16170-3.